Redeye initiates coverage of Alzinova, an early-stage biotech that develops a disease-modifying vaccine against Alzheimer’s disease. We view Alzinova’s vaccine candidate, ALZ-101, as scientifically and empirically strong and persuasive. There are several catalysts of importance for the stock, short- and mid-term.